8-K Announcements
6Material company update
Mar 26, 2026·SEC
Material company update
Nov 12, 2025·SEC
Material company update
Sep 25, 2025·SEC
Lucid Diagnostics Inc.(LUCD)Earnings, Financials & Key Ratios
LUCD•NASDAQ
$1.05
$137M mkt cap·Price updated May 7, 2026
AboutLucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.Show more
- Revenue$4M+79.0%
- EBITDA-$45M+2.4%
- Net Income-$46M+13.6%
- EPS (Diluted)-1.05+16.7%
- Gross Margin-90.2%+63.8%
- EBITDA Margin-1032.79%+45.5%
- Operating Margin-1059.64%+46.9%
- Net Margin-1047.61%+51.7%
- ROE-2956.43%-482.0%
- Debt/Equity3.94
- Interest Coverage-1771.23-1419.8%
LUCD Key Insights
Lucid Diagnostics Inc. (LUCD) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗High debt to equity ratio of 3.9x
- ✗Negative free cash flow
- ✗Shares diluted 21.0% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
LUCD Price & Volume
Lucid Diagnostics Inc. (LUCD) stock price & volume — 10-year historical chart
Loading chart...
LUCD Growth Metrics
Lucid Diagnostics Inc. (LUCD) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years105.61%
TTM28885.15%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-23193.96%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM21.08%
Return on Capital
10 Years-632.57%
5 Years-632.57%
3 Years-799.09%
Last Year-1813.43%
LUCD Recent Earnings
Lucid Diagnostics Inc. (LUCD) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)●Beat Revenue 2/12 qtrs (17%)
Q2 2026Latest
Mar 26, 2026EPS
$0.10
Est $0.07
-42.9%
Revenue
$2M
Est $1M
+10.4%
Q2 2026
Mar 25, 2026EPS
$0.10
Est $0.07
-42.9%
Revenue
$2M
Est $1M
+10.4%
Q4 2025
Nov 12, 2025EPS
$0.10
Est $0.06
-66.7%
Revenue
$1M
Est $1M
-12.7%
Q3 2025
Aug 13, 2025EPS
$0.10
Est $0.09
-11.1%
Revenue
$1M
Est $2M
-32.1%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 26, 2026 | $0.10vs $0.07-42.9% | $2Mvs $1M+10.4% |
| Q2 2026 | Mar 25, 2026 | $0.10vs $0.07-42.9% | $2Mvs $1M+10.4% |
| Q4 2025 | Nov 12, 2025 | $0.10vs $0.06-66.7% | $1Mvs $1M-12.7% |
| Q3 2025 | Aug 13, 2025 | $0.10vs $0.09-11.1% | $1Mvs $2M-32.1% |
Based on last 12 quarters of dataView full earnings history →
LUCD Peer Comparison
Lucid Diagnostics Inc. (LUCD) competitors in Surgical tools, endoscopy, and robotics — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 GKOS | 7.85B | 134.15 | -40.90 | 32.33% | -34.34% | -26.46% | 0.21 | |
 NVCR | 1.92B | 16.83 | -13.80 | 8.28% | -25.66% | -50.82% | 0.85 | |
 NNOX | 115.07M | 1.76 | -1.93 | 13.91% | -452.82% | -35.55% | 0.04 | |
 CDXS | 234.44M | 2.58 | -5.16 | 18.61% | -62.47% | -90.51% | 1.45 | |
 EXAS | 20.02B | 104.91 | -95.37 | 17.69% | -6.4% | -8.66% | 1.05 | |
 NTRA | 31.16B | 219.82 | -144.62 | 35.9% | -9.03% | -15.28% | 0.13 | |
 GUTS | 114.74M | 0.75 | -0.40 | -100% | -7.44% | 6.52 | ||
 MDT | 99.94B | 77.96 | 21.60 | 3.62% | 13% | 9.45% | 0.59 |
Compare LUCD vs Peers
Lucid Diagnostics Inc. (LUCD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
LUCD Income Statement
Lucid Diagnostics Inc. (LUCD) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 500K | 377K | 2.43M | 4.35M | 4.25M |
| Revenue Growth % | - | - | - | - | -24.6% | 544.03% | 79% | 28885.15% |
| Cost of Goods Sold | 0 | 0 | 0 | 585K | 3.61M | 8.48M | 8.27M | 1.7B |
| COGS % of Revenue | - | - | - | 117% | 958.62% | 349.18% | 190.2% | - |
| Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | -85K▲ 0% | -3.24M▼ 3708.2% | -6.05M▼ 86.9% | -3.92M▲ 35.2% | -488.29M▲ 0% |
| Gross Margin % | - | - | - | -17% | -858.62% | -249.18% | -90.2% | -40.22% |
| Gross Profit Growth % | - | - | - | - | -3708.24% | -86.9% | 35.21% | - |
| Operating Expenses | 1.13M | 4.42M | 8.28M | 27.33M | 52.93M | 42.43M | 42.13M | 11.31B |
| OpEx % of Revenue | - | - | - | 5466.8% | 14040.85% | 1747.61% | 969.44% | - |
| Selling, General & Admin | 410.29K | 958.72K | 2.84M | 18.04M | 39.82M | 35.66M | 36.62B | 19.54B |
| SG&A % of Revenue | - | - | - | 3607.6% | 10562.07% | 1468.62% | 842590.89% | - |
| Research & Development | 715.63K | 3.46M | 5.44M | 9.3M | 11.47M | 7.25M | 5.99M | 1.28B |
| R&D % of Revenue | - | - | - | 1859.2% | 3041.38% | 298.68% | 137.87% | - |
| Other Operating Expenses | 0 | 278 | 0 | 0 | 1.65M | -478K | -36.58B | 211K |
| Operating Income | -1.13M▲ 0% | -4.42M▼ 292.6% | -8.28M▼ 87.3% | -27.42M▼ 231.1% | -56.17M▼ 104.9% | -48.48M▲ 13.7% | -46.05M▲ 5.0% | -11.8B▲ 0% |
| Operating Margin % | - | - | - | -5483.8% | -14899.47% | -1996.79% | -1059.64% | -971.45% |
| Operating Income Growth % | - | -292.63% | -87.29% | -231.15% | -104.86% | 13.69% | 5.01% | - |
| EBITDA | 563K | 0 | 0 | -27.41M | -54.23M | -45.98M | -44.88M | -11.35B |
| EBITDA Margin % | - | - | - | -5483% | -14385.94% | -1893.86% | -1032.79% | -935.09% |
| EBITDA Growth % | - | -100% | - | - | -97.83% | 15.22% | 2.39% | -25966.54% |
| D&A (Non-Cash Add-back) | 1.69M | 4.42M | 8.28M | 4K | 1.94M | 2.5M | 1.17M | 441.44M |
| EBIT | -1.13M | -4.42M | -8.28M | -27.42M | -56.17M | -52.25M | -45.5M | -10.44B |
| Net Interest Income | 0 | 0 | 0 | -659K | 80K | 8K | 296K | 99.22M |
| Interest Income | 0 | 0 | 0 | 0 | 88K | 424K | 322K | 101.24M |
| Interest Expense | 0 | 0 | 0 | 659K | 8K | 416K | 26K | 2.02M |
| Other Income/Expense | 0 | 0 | 0 | -659K | 0 | -4.18M | 523K | 1.36B |
| Pretax Income | -1.13M▲ 0% | -4.42M▼ 292.6% | -8.28M▼ 87.3% | -28.08M▼ 239.1% | -56.17M▼ 100.1% | -52.67M▲ 6.2% | -45.53M▲ 13.6% | -10.44B▲ 0% |
| Pretax Margin % | - | - | - | -5615.6% | -14899.47% | -2169.11% | -1047.61% | -245605.94% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -1.13M▲ 0% | -4.42M▼ 292.6% | -8.28M▼ 87.3% | -28.08M▼ 239.1% | -56.17M▼ 100.1% | -52.67M▲ 6.2% | -45.53M▲ 13.6% | -10.44B▲ 0% |
| Net Margin % | - | - | - | -5615.6% | -14899.47% | -2169.11% | -1047.61% | -859.82% |
| Net Income Growth % | - | -292.63% | -87.29% | -239.11% | -100.05% | 6.24% | 13.55% | -23193.96% |
| Net Income (Continuing) | -1.13M | -4.42M | -8.28M | -28.08M | -56.17M | -52.67M | -45.53M | -10.44B |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.03▲ 0% | -0.12▼ 294.7% | -0.22▼ 83.3% | -0.78▼ 254.5% | -1.55▼ 98.7% | -1.26▲ 18.7% | -1.05▲ 16.7% | -96.51▲ 0% |
| EPS Growth % | - | -294.74% | -83.33% | -254.55% | -98.72% | 18.71% | 16.67% | 21.08% |
| EPS (Basic) | -0.03 | -0.12 | -0.22 | -0.78 | -1.55 | -1.26 | -1.05 | - |
| Diluted Shares Outstanding | 36.99M | 36.99M | 36.99M | 36.06M | 36.17M | 41.76M | 50.52M | 108.18M |
| Basic Shares Outstanding | 36.99M | 36.99M | 36.99M | 36.06M | 36.17M | 41.76M | 50.52M | 108.18M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
LUCD Balance Sheet
Lucid Diagnostics Inc. (LUCD) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 17.8K | 390.9K | 1.44M | 57.3M | 24.36M | 22.07M | 25.15M | 49.84M |
| Cash & Short-Term Investments | 17.8K | 156.4K | 111K | 53.66M | 22.47M | 18.9M | 22.36M | 47.33M |
| Cash Only | 17.8K | 156.4K | 111K | 53.66M | 22.47M | 18.9M | 22.36M | 47.33M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 | 200K | 17K | 45K | 405K | 550K |
| Days Sales Outstanding | - | - | - | 146 | 16.46 | 6.76 | 34.01 | 29.82 |
| Inventory | 0 | 0 | 834K | 493K | 111K | 278K | 341K | 856K |
| Days Inventory Outstanding | - | - | - | 307.6 | 11.21 | 11.97 | 15.06 | 0.14 |
| Other Current Assets | 0 | 118.09K | 0 | 0 | 0 | 1.98M | 0 | 1.04M |
| Total Non-Current Assets | 0 | 643K | 755K | 1.7M | 8.15M | 5.2M | 5.57M | 3.36M |
| Property, Plant & Equipment | 0 | 0 | 0 | 971K | 3.6M | 2.64M | 3.7M | 2.88M |
| Fixed Asset Turnover | - | - | - | 0.51x | 0.10x | 0.92x | 1.17x | 1.28x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 3.44M | 1.42M | 736K | 421K |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 643K | 755K | 725K | 1.11M | 1.13M | 1.13M | 3.44M |
| Total Assets | 17.8K▲ 0% | 1.03M▲ 5708.4% | 2.19M▲ 112.3% | 59M▲ 2587.9% | 32.51M▼ 44.9% | 27.27M▼ 16.1% | 30.71M▲ 12.6% | 53.2M▲ 0% |
| Asset Turnover | - | - | - | 0.01x | 0.01x | 0.09x | 0.14x | 0.11x |
| Asset Growth % | - | 5708.43% | 112.3% | 2587.88% | -44.9% | -16.12% | 12.63% | 163.73% |
| Total Current Liabilities | 1.08M | 6.34M | 15.71M | 4.26M | 8.43M | 29.38M | 23.52M | 26.21M |
| Accounts Payable | 497.23K | 799.08K | 2.06M | 1.49M | 1.06M | 1.15M | 1.24M | 751K |
| Days Payables Outstanding | - | - | - | 929.66 | 106.65 | 49.34 | 54.8 | 0.2 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 13.95M | 18.6M | 23.18M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 936K | 0 | 0 |
| Other Current Liabilities | 583.26K | 5.32M | 0 | 557K | 5.53M | 791K | 1.35M | 2.28M |
| Current Ratio | 0.02x | 0.06x | 0.09x | 13.45x | 2.89x | 0.75x | 1.07x | 1.07x |
| Quick Ratio | 0.02x | 0.06x | 0.04x | 13.34x | 2.88x | 0.74x | 1.05x | 1.05x |
| Cash Conversion Cycle | - | - | - | -476.06 | -78.98 | -30.6 | -5.73 | 29.76 |
| Total Non-Current Liabilities | 0 | 0 | 0 | 0 | 1.04M | 199K | 1.8M | 1.16M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 1.04M | 199K | 1.8M | 5.94M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 1.08M | 6.34M | 15.71M | 4.26M | 9.46M | 29.58M | 25.32M | 27.36M |
| Total Debt | 0 | 0 | 0 | 0 | 2M | 15.26M | 21.25M | 24.34M |
| Net Debt | -17.8K | -156.4K | -111K | -53.66M | -20.48M | -3.64M | -1.1M | -23M |
| Debt / Equity | - | - | - | - | 0.09x | - | 3.94x | 3.94x |
| Debt / EBITDA | - | - | - | - | - | - | - | -0.00x |
| Net Debt / EBITDA | -0.03x | - | - | - | - | - | - | 0.00x |
| Interest Coverage | - | - | - | -41.61x | -7021.38x | -116.54x | -1771.23x | -5162.15x |
| Total Equity | -1.06M▲ 0% | -5.31M▼ 399.6% | -13.52M▼ 154.6% | 54.74M▲ 504.9% | 23.05M▼ 57.9% | -2.31M▼ 110.0% | 5.39M▲ 333.3% | 25.84M▲ 0% |
| Equity Growth % | - | -399.61% | -154.61% | 504.93% | -57.9% | -110.03% | 333.28% | 444.89% |
| Book Value per Share | -0.03 | -0.14 | -0.37 | 1.52 | 0.64 | -0.06 | 0.11 | 0.24 |
| Total Shareholders' Equity | -1.06M | -5.31M | -13.52M | 54.74M | 23.05M | -2.31M | 5.39M | 25.84M |
| Common Stock | 10K | 14.11K | 14K | 35K | 41K | 42K | 63K | 131K |
| Retained Earnings | -1.13M | -5.55M | -13.83M | -41.9M | -98.08M | -150.74M | -203.77M | -258.07M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
LUCD Cash Flow Statement
Lucid Diagnostics Inc. (LUCD) cash flow — operating, investing & free cash flow history
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -113.7K | -2.36M | -5.63M | -17.67M | -29.68M | -32.82M | -44.14M | -44.14M |
| Operating CF Margin % | - | - | - | -3533.6% | -7874.01% | -1351.61% | -1015.65% | - |
| Operating CF Growth % | - | -1976.87% | -138.36% | -213.89% | -68.02% | -10.55% | -34.5% | 3.32% |
| Net Income | -1.13M | -4.42M | -8.28M | -28.08M | -56.17M | -52.67M | -45.53M | -10.44B |
| Depreciation & Amortization | 0 | 0 | 0 | 4K | 1.94M | 2.5M | 1.17M | 885K |
| Stock-Based Compensation | 79.85K | 0 | 65K | 0 | 14.99M | 6.82M | 4.53M | 3.35M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -205.06K | 173.94K | 459 | 9.6M | 653K | 4.85M | 119K | 7.08M |
| Working Capital Changes | 720.05K | 1.89M | 2.59M | 807K | 8.91M | 5.67M | -4.43M | -1.81M |
| Change in Receivables | 0 | 0 | 0 | -200K | 183K | -28K | 0 | -512K |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 497.23K | 301.85K | 1.15M | -665K | -445K | 89K | 96K | -384K |
| Cash from Investing | 0 | 0 | 0 | -862K | -4.11M | -221K | -646K | -405K |
| Capital Expenditures | 0 | 0 | 0 | -862K | -908K | -221K | -296K | -405K |
| CapEx % of Revenue | - | - | - | 172.4% | 240.85% | 9.1% | 6.81% | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | -3.2M | 0 | -350K | 0 |
| Cash from Financing | 131.5K | 2.5M | 5.58M | 72.08M | 2.61M | 29.46M | 48.25M | 77.03M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 10M | 18M | 18.36M |
| Equity Issued (Net) | 0 | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 3M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 131.5K | 0 | 0 | -5.66M | 804K | 551K | 451K | 154K |
| Net Change in Cash | 17.8K▲ 0% | 138.6K▲ 678.7% | -45.15K▼ 132.6% | 53.54M▲ 118695.6% | -31.18M▼ 158.2% | -3.58M▲ 88.5% | 3.46M▲ 196.8% | 32.84M▲ 0% |
| Free Cash Flow | -113.7K▲ 0% | -2.36M▼ 1976.9% | -5.63M▼ 138.4% | -18.53M▼ 229.2% | -30.59M▼ 65.1% | -33.04M▼ 8.0% | -44.79M▼ 35.6% | -44.18M▲ 0% |
| FCF Margin % | - | - | - | -3706% | -8114.85% | -1360.71% | -1030.51% | -3.64% |
| FCF Growth % | - | -1976.87% | -138.36% | -229.21% | -65.1% | -7.99% | -35.56% | 1.4% |
| FCF per Share | -0.00 | -0.06 | -0.15 | -0.51 | -0.85 | -0.79 | -0.89 | -0.89 |
| FCF Conversion (FCF/Net Income) | 0.10x | 0.53x | 0.68x | 0.63x | 0.53x | 0.62x | 0.97x | 0.00x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
LUCD Key Ratios
Lucid Diagnostics Inc. (LUCD) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -136.23% | -144.42% | -507.97% | -2956.43% | -40409.86% |
| Return on Invested Capital (ROIC) | - | - | - | -2305.24% | - | - | -220170.1% |
| Gross Margin | - | - | -17% | -858.62% | -249.18% | -90.2% | -40.22% |
| Net Margin | - | - | -5615.6% | -14899.47% | -2169.11% | -1047.61% | -859.82% |
| Debt / Equity | - | - | - | 0.09x | - | 3.94x | 3.94x |
| Interest Coverage | - | - | -41.61x | -7021.38x | -116.54x | -1771.23x | -5162.15x |
| FCF Conversion | 0.53x | 0.68x | 0.63x | 0.53x | 0.62x | 0.97x | 0.00x |
| Revenue Growth | - | - | - | -24.6% | 544.03% | 79% | 28885.15% |
LUCD SEC Filings & Documents
Lucid Diagnostics Inc. (LUCD) SEC filings — annual & quarterly reports (10-K, 10-Q)
LUCD Frequently Asked Questions
Lucid Diagnostics Inc. (LUCD) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Lucid Diagnostics Inc. (LUCD) reported $4.3M in revenue for fiscal year 2024.
Lucid Diagnostics Inc. (LUCD) grew revenue by 79.0% over the past year. This is strong growth.
Lucid Diagnostics Inc. (LUCD) reported a net loss of $10.44B for fiscal year 2024.
Dividend & Returns
Lucid Diagnostics Inc. (LUCD) has a return on equity (ROE) of -2956.4%. Negative ROE indicates the company is unprofitable.
Lucid Diagnostics Inc. (LUCD) had negative free cash flow of $44.2M in fiscal year 2024, likely due to heavy capital investments.
Explore More LUCD
Lucid Diagnostics Inc. (LUCD) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates